title: Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes.
abstract: Norcantharidin (NCTD) is the demethylated analogue of cantharidin. In this study, multi-parameter assessments of morphological alterations, clonogenic efficiency, cell growth curves, DNA synthesis, and DNA strand break were employed to determine and compare the cytotoxic effects of NCTD on oral cancer KB cell line and normal buccal keratinocytes. The results showed NCTD induced significant cytotoxicity in KB cells after 24 h of exposure. Normal buccal keratinocytes were more resistant to NCTD induced cytotoxicity. The IC(50) of 24 h NCTD treatment for KB and keratinocytes were 15.06 and 216.29 microg/ml, respectively with a keratinocyte/KB selective index of 14.36. Anoikis and membrane blebbing, morphological characterization of apoptosis, were observed in about 90% of KB cells after exposure to 100 microg/ml of NCTD for 24 h compared to about 30% in keratinocytes. In addition, inhibition of colony formation was noted in KB cells even when exposed to low concentration of drug (5 microg/ml) for a short period of time (6 h). NCTD inhibited subsequent cell proliferation in KB but growth of normal keratinocytes was retarded only temporarily. NCTD inhibited DNA synthesis in both KB and normal keratinocytes. However, keratinocytes were more sensitive to DNA synthesis inhibition by low dose of NCTD. Significant DNA strand break was noted in KB cells only after cell viability was reduced to less than 60% of the control. In comparison, normal keratinocytes were resistant to NCTD induced DNA strand break. These results indicated KB cells were more sensitive to NCTD induced cytotoxicity compared to normal keratinocytes. NCTD may be of value in treating oral cancers. The underlying mechanisms of the differential actions of NCTD on these two cell types are worthy of further investigations.
authors.affiliation: School of Dentistry, National Taiwan University Medical Center, 1 Chang-Teh Street, Taipei, Taiwan 10016, ROC.
authors.forename: S H
authors.initials: SH
authors.lastname: Kok
authors.forename: C Y
authors.initials: CY
authors.lastname: Hong
authors.forename: M Y P
authors.initials: MY
authors.lastname: Kuo
authors.forename: C H K
authors.initials: CH
authors.lastname: Lee
authors.forename: J J
authors.initials: JJ
authors.lastname: Lee
authors.forename: I U
authors.initials: IU
authors.lastname: Lou
authors.forename: M S
authors.initials: MS
authors.lastname: Lee
authors.forename: M
authors.initials: M
authors.lastname: Hsiao
authors.forename: S K
authors.initials: SK
authors.lastname: Lin
mesh_terms: D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000627:therapeutic use*; D002455:Cell Division / Q000187:drug effects; D004249:DNA Damage; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004305:Dose-Response Relationship, Drug; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects; D009061:Mouth Mucosa; D009062:Mouth Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D004273:DNA, Neoplasm; C069741:norcantharidin